Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases

Pharmacology, Toxicology and Pharmaceutical Science

• Growth Factor 100%
• Denosumab 100%
• Bone Metastasis 100%
• Zoledronic Acid 100%
• Normal Human 30%
• Osteoclast Differentiation Factor 30%
• Jaw Osteonecrosis 20%
• Wound Healing Impairment 20%
• Drug 10%
• Enzyme-Linked Immunosorbent Assay 10%
• Vasculotropin 10%
• Side Effect 10%
• Wound Healing 10%
• Platelet Derived Growth Factor BB 10%

Medicine and Dentistry

• Bone Metastasis 100%
• Zoledronic Acid 100%
• Platelet-Rich Fibrin 100%
• Denosumab 100%
• Osteonecrosis of the Jaw 20%
• Volunteer 20%
• Wound Healing Impairment 20%
• Wound Healing 10%
• Side Effect 10%
• In Vitro 10%
• Vasculotropin 10%
• Platelet Derived Growth Factor BB 10%
• Drug 10%

Immunology and Microbiology

• Growth Factor 100%
• Denosumab 100%
• Normal Human 30%
• RANKL 30%
• Jaw 20%
• Wound Healing Impairment 20%
• ELISA 10%
• Platelet Derived Growth Factor BB 10%